P-103 Refinement of Population Pharmacokinetic Model of Certolizumab Pegol in Crohn's Disease Patients to Account for Time Varying Nature of Covariates. (March 2016)

• Record Type: Journal Article
• Authors: Casteele, Niels Vande; Mould, Diane; Kosutic, Gordana; Spearman, Marshall; Feagan, Brian; Sandborn, William
• Is Part Of: Inflammatory bowel diseases. Volume 22(2016:Mar.)Supplement 1
• Publication Date: 2016-03
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1097/01.MIB.0000480258.39258.e5
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : Background: A population pharmacokinetic (pop PK) analysis for certolizumab pegol (CZP) was developed in patients with Crohn's disease (CD), 1 which consisted of a baseline concentration, first-order absorption, and one-compartment disposition. Covariates that influence the disposition of CZP were identified, but only baseline values were used. We subsequently refined the existing model so that time-varying demographic and pathophysiologic characteristics on the estimated variability were taken into account. Methods: Data collected from 2157 patients with CD in 9 studies were analyzed using nonlinear mixed effects modeling (NONMEM) software. The CZP concentration-time data were described by a one-compartment pop PK model with first-order absorption and one-compartment disposition with linear, time-dependent elimination. Results: Pop PK estimates, based on the final covariate model, were absorption rate (1.83/day), clearance (CL; 0.527 L/day), and apparent volume of distribution (V; 8.33 L). CZP exhibited interindividual variability for CL of 19.6%. Anti-CZP antibodies were included as a continuous, time-varying covariate on CZP CL in the structural model. CZP CL increased from 142% to 174% for a typical patient with CD over the 5th to the 95th percentile of the anti-CZP antibody range (respectively, 2.5–212.3 units/mL). Covariate analysis showed that time-varying albumin concentration, C-reactive protein concentration, and body weight influenced CZP CL. Female gender was associated with a modest increase in CZP CL. Time-varying body weight influenced CZP V. Conclusions: A pop PK model that takes into account the time-varying nature of patients' covariates reduced the between-patient variability on CZP CL from 27.5%1 to 19.6%, extending learnings from the previous model that included baseline values. By taking into account anti-CZP antibodies as a time-varying and continuous variable in the updated model, future analyses can assess the relative influence of anti-CZP antibodies on CZP CL. This is an important improvement, as inflammatory bowel disease patient covariates are often time-dependent, making this model more reflective of patient drug exposure with sustained treatment.